HeartLife Academy

Managing and Understanding Heart Failure Medications

Heart failure medications can feel overwhelming — complex names, multiple classes, and questions about side effects and interactions. This course breaks it down clearly. You'll explore the major drug classes used in heart failure management — ACE inhibitors, ARBs, ARNIs, beta blockers, diuretics, MRAs, SGLT2 inhibitors, and sinus node inhibitors — learning what each does, why it's prescribed, and what to watch for. Designed for patients and caregivers, this course helps you understand your treatment plan and have confident, informed conversations with your care team.

By the end of this course, you will be able to:

  • Describe the goals of heart failure pharmacotherapy and the importance of medication adherence.
  • Explain the mechanisms and clinical benefits of ACE inhibitors, ARBs, and ARNIs in heart failure.
  • Describe how beta blockers reduce cardiac workload and mortality in heart failure.
  • Identify the role of diuretics in managing fluid congestion in heart failure.
  • Explain how MRAs reduce aldosterone-driven cardiac remodelling.
  • Describe the cardiovascular and renal benefits of SGLT2 inhibitors in heart failure.
  • Explain how sinus node inhibitors reduce heart rate and improve exercise tolerance in heart failure.

Course Content

Not started

Introduction to HF Medications

You don't currently have access to this content
Not started

Module 1: ACE / ARB / ARNI

You don't currently have access to this content
Not started

Module 2: Beta Blockers

You don't currently have access to this content
Not started

Module 3: Diuretics

You don't currently have access to this content
Not started

Module 4: MRAs (Mineralocorticoid Receptor Antagonists)

You don't currently have access to this content
Not started

Module 5: Sinus Node Inhibitors

You don't currently have access to this content
Not started

Module 6: SGLT2 Inhibitors

You don't currently have access to this content

Learner Reviews

Funding for this course was provided by unrestricted educational grants from

AstraZenecaBoehringer Ingelheim